Stockscreener 앱 받기
8.11
2.27%
0.18
전일 마감가:
$7.93
열려 있는:
$7.92
하루 거래량:
32,324
Relative Volume:
1.65
시가총액:
$36.92M
수익:
$85.53M
순이익/손실:
$-9.78M
주가수익비율:
-3.6944
EPS:
-2.1952
순현금흐름:
$1.28M
1주 성능:
+7.42%
1개월 성능:
+32.95%
6개월 성능:
+32.15%
1년 성능:
+63.84%
1일 변동 폭
$7.90
$8.12
1주일 범위
$7.36
$8.12
52주 변동 폭
$3.755
$9.40
Harvard Bioscience Inc Stock (HBIO) Company Profile
명칭
Harvard Bioscience Inc
전화
(508) 893-8999
주소
84 OCTOBER HILL RD, HOLLISTON, MA
Compare HBIO vs ISRG, BDX, ALC, RMD, MDLN
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HBIO
Harvard Bioscience Inc
|
8.11 | 34.37M | 85.53M | -9.78M | 1.28M | -2.1952 |
ISRG
Intuitive Surgical Inc
|
376.86 | 132.30B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
188.11 | 51.11B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
72.06 | 35.25B | 10.63B | 819.00M | 1.59B | 1.6577 |
RMD
Resmed Inc
|
240.10 | 32.95B | 5.54B | 1.52B | 1.74B | 10.37 |
MDLN
Medline Inc
|
35.03 | 28.58B | 29.14B | 1.07B | 1.05B | 1.1956 |
Harvard Bioscience Inc Stock (HBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-09 | 다운그레이드 | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-03-10 | 업그레이드 | The Benchmark Company | Speculative Buy → Buy |
| 2021-01-07 | 업그레이드 | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-09 | 개시 | Northland Capital | Outperform |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Overweight |
| 2019-07-08 | 다운그레이드 | Janney | Buy → Neutral |
| 2018-01-24 | 재확인 | Janney | Buy |
| 2018-01-23 | 재확인 | The Benchmark Company | Buy |
| 2016-11-17 | 개시 | Singular Research | Buy |
| 2015-07-28 | 개시 | The Benchmark Company | Buy |
모두보기
Harvard Bioscience Inc 주식(HBIO)의 최신 뉴스
Harvard Bioscience Insider Confidence Rewarded, Stock Hits US$32m Market Cap - Sahm
Harvard Bioscience (HBIO) Q2 2026 Earnings Call Transcript - The Globe and Mail
HBIO Stock Price, Quote & Chart - ChartMill
Benchmark raises Harvard Bioscience stock price target on revenue beat By Investing.com - Investing.com South Africa
HBIO Maintained by Benchmark -- Price Target Raised to $7.50 - GuruFocus
Benchmark raises Harvard Bioscience stock price target on revenue beat - Investing.com
Harvard Bioscience, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:HBIO) 2026-08-12 - Seeking Alpha
Harvard Bioscience, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
HARVARD BIOSCIENCE INC 2026: Revenue $22.73M, EPS ($0.64) — 10-Q Summary - TradingView
Harvard Bioscience (NASDAQ: HBIO) grows Q2 sales but faces higher debt costs - Stock Titan
Harvard Bioscience Inc (HBIO) (Q2 2026) Earnings Call Highlights - GuruFocus
HBIO Looks 66.8% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
Harvard Bioscience Inc (HBIO) (Q2 2026) Earnings Call Highlights: Revenue Surges 11% and ... - Yahoo Finance
Harvard Bioscience Releases Q2 2026 Financial Results - AlphaStreet
Earnings call transcript: Harvard Bioscience tops Q2 2026 forecasts, raises outlook - Investing.com Nigeria
HBio Q2 2026 slides: revenue up 11%, China growth drives guidance raise - Investing.com Nigeria
Harvard Bioscience beats Q2 estimates and raises 2026 revenue guidance - Yahoo Finance
Harvard Bioscience beats estimates, raises 2026 guidance - Investing.com
Harvard Bioscience Raises Full-Year 2026 Revenue Guidance After Strong Second-Quarter Growth - Minichart
Why is Harvard Bioscience stock gaining today? By Investing.com - Investing.com Canada
Is Harvard Bioscience Inc (HBIO) Undervalued After Q2 Earnings B - GuruFocus
Harvard Bioscience beats estimates, raises 2026 guidance By Investing.com - Investing.com South Africa
Harvard Bioscience Announces Second Quarter 2026 Financial Results - The Manila Times
Harvard Bioscience: Q2 Earnings Snapshot - marketscreener.com
Harvard Bioscience Q2 revenue rises on telemetry demand, lifts 2026 outlook - TradingView
Harvard Bioscience Q2 Revenue Rises 11 Percent to $22.7 Million - Quiver Quantitative
Harvard Bioscience (HBIO) grows Q2 2026 sales but stays in loss - Stock Titan
BRIEF-Harvard Bioscience Q2 Net Income USD -2.91 Million - TradingView
Harvard Bioscience, Inc. Provides Earnings Guidance for the Third Quarter of 2026 - marketscreener.com
Harvard Bioscience Inc (HBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Harvard Bioscience Inc expected to post a loss of 21 cents a shareEarnings Preview - TradingView
Harvard Bioscience Q2 Results: Earnings Call Set for August 11 - scanx.trade
Harvard Bioscience Schedules Second Quarter 2026 Earnings Conference Call for August 11, 2026 at 8:00 AM ET - The Manila Times
Harvard Bioscience Schedules Second Quarter 2026 Earnings Conference Call for August 11, 2026 ... - Caledonian Record
Harvard Bioscience Inc (HBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Harvard Bioscience Inc (HBIO) Cash Flow - TradingKey
Harvard Bioscience Inc (HBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Harvard Bioscience Inc (HBIO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Harvard Bioscience Inc (HBIO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Harvard Bioscience Inc (HBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
HBIO|Harvard Bioscience Inc|Price:6.000|Chg%:-0.190 - TradingKey
Harvard Bioscience, Inc. Revenue Breakdown – MUN:HBI0 - TradingView
Harvard Bioscience, Inc. Revenue Breakdown – LS:A423J5 - TradingView
Harvard Bioscience, Inc. Revenue Breakdown – NASDAQ:HBIO - TradingView
Harvard Bioscience, Inc. Revenue Breakdown – LSX:A423J5 - TradingView
Harvard Bioscience Inc (HBIO) Institutional Confidence - TradingKey
HBIO Q2'26 Earnings: revenue estimate is 21.45M USD - TradingView
HBIO Q1 2026 Earnings: EPS Beat Driven by Cost Control Amid Challenging QuarterEarnings Season Review - Vinanet
Harvard Bioscience focuses on life science instruments as investors weigh long-term demand - ad-hoc-news.de
Harvard Bioscience (HBIO) Slips 4.5% as Selling Pressure Tests Key SupportETF Inflow Streak - po-news-eg.net
Harvard Bioscience focuses on lab equipment growth - Ad-hoc-news.de
Harvard Bioscience Inc (HBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Harvard Bioscience Inc 주식 (HBIO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| DENELSKY STEPHEN J | Director |
Mar 17 '26 |
Buy |
4.87 |
10,000 |
48,700 |
21,000 |
| Snider William | Director |
Mar 16 '26 |
Buy |
4.99 |
12,525 |
62,500 |
23,525 |
| Snider William | Director |
Mar 17 '26 |
Buy |
4.85 |
8,475 |
41,104 |
32,000 |
| Duke John D | Chief Executive Officer |
Mar 16 '26 |
Buy |
5.01 |
5,000 |
25,050 |
105,000 |
1.40%
0.50%
자본화:
|
볼륨(24시간):